Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials
Topline data from two phase 3 trials evaluating orforglipron,! an oral GLP-1 receptor agonist, in patients with type 2 diabetes, were announced.
The randomized, active-controlled, open-label ACHIEVE-2 trial compared the efficacy and safety of orforglipron with dapagliflozin in adults with T2D and inadequate glycemic control with metformin.
- Study participants (N=962; baseline hemoglobin A1c [HbA1c] of 8.1%) were randomly assigned to receive orforglipron or dapagliflozin once daily, alongside background metformin therapy.
- The primary endpoint was the change from baseline to week 40 in HbA1c.
Author's summary: Orforglipron lowers HbA1c significantly.
More News
- Nobel Prize banquet chefs and pastry chef 2025
- Spillcontrol – Spill Control
- Golden State Warriors vs Cleveland Cavaliers | Live Play-By-Play & Reactions
- Where the Chefs Eat: Skye McAlpine’s Venice
- Golden State Warriors vs Cleveland Cavaliers regular season game: Full injury report, who's out, and more
- CHEFS (@chefs_podcast) - Instagram photos and videos
- Is London The Top City In The World For This Cuisine? These Chefs Say Yes
- Spill and pollution response
- Oil spills and technological cooperation for their prevention
- Solidarity on Trial in Greece